#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mu­tant non-small cell lung can­cer has turned up some promis­ing — al­though de­cid­ed­ly ear­ly — re­sults, fu­el­ing the idea that there’s yet room to one up on third-gen­er­a­tion ty­ro­sine ki­nase in­hibitors.

Twen­ty out of 20 ad­vanced NSCLC pa­tients had a re­sponse af­ter tak­ing a com­bi­na­tion of an in-house TKI dubbed laz­er­tinib and ami­van­tam­ab, a bis­pe­cif­ic an­ti­body tar­get­ing both EGFR and cMET en­gi­neered on part­ner Gen­mab’s plat­form, J&J re­port­ed at ES­MO. All were treat­ment-naïve, and none has seen their can­cer progress at a me­di­an fol­low-up of sev­en months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.